Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. MarketScreener Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Women under 60 face higher risk of rare clotting after AstraZeneca shot - German official

04/07/2021 | 12:51pm EDT

BERLIN/ZURICH, April 7 (Reuters) - Instances of a very rare clotting condition in women aged under 60 who received AstraZeneca's COVID-19 vaccine were 20 times higher than would normally be expected, Christian Bogdan, a member of Germany's vaccine committee, said on Wednesday.

His comments came as the European Medicines Agency (EMA) and Britain's medical regulator acknowledged a possible link between the AstraZeneca vaccine to rare blood clots with low blood platelet counts. The EMA conducted an in-depth review of 86 cases, including 18 fatalities.

Most were in women, but with just 169 total cases reported to the EMA after 34 million doses had been given, they appear to be extremely rare. In comparison, four women out of 10,000 would get a blood clot from taking oral contraception.

Bogdan did not specify how many cases of blood clots with low blood platelet counts would be expected in a normal population, but said their higher prevalence in one population group over a defined timeframe represented a "very clear risk signal".

"We looked at how many cases occur in society as a background incidence, and compared that with cases observed between four and 16 days after vaccination," he told an online briefing.

"When you take that into account, then you come to an observed-to-expected ratio...of 20 (times higher) in women between 20 and 59 years old," he said.

The German committee recommended last week that people under 60 who had received one AstraZeneca shot should get a second dose of another vaccine.

Health experts also told the briefing, organised by the Science Media Center, that more research was needed to discover what may predispose people to clots with low blood platelet counts, and as well as the precise mechanism that leads to them.

One explanation, cited by the German vaccine committee members on Wednesday, suggests AstraZeneca's vaccine is associated with production of an unusual antibody that activates blood platelets and causes the rare clots; other investigators are investigating a link to birth control pills.

Andreas Greinacher, a scientist from Germany's Greifswald University whose team has linked the antibody to the rare clots, said his work indicates that neither birth control nor having a clotting factor mutation, called Factor V Leiden, play any role.

"Many individuals are afraid who have one of the common prothombotic underlying conditions like taking hormonal contraceptives or having Factor V Leiden, but all those factors do not modulate the risk for these antibodies," Greinacher told Reuters. "It's not a game changer, at all."

(Reporting by John Miller and Douglas Busvine; editing by David Evans and Philippa Fletcher)

© Reuters 2021
All news about ASTRAZENECA PLC
04/16ASTRAZENECA  : Quebec to deploy sound trucks in Montreal to announce mobile vacc..
04/16ASTRAZENECA  : Doctors say lowering age cutoff for AstraZeneca vaccine makes sen..
04/16Consumer Cos Climb On Reopening Optimism -- Consumer Roundup
04/16Health Care Up After Strong Start to Earnings Season -- Health Care Roundup
04/16Vaccine Manufacturing Issues Force Moderna to Cut Supplies to Canada, U.K.
04/16No Causal Link Found So Far Between J&J's Covid-19 Vaccine and Blood-Clot Cas..
04/16ASTRAZENECA  : German's IDT to make 10M AstraZeneca vaccine doses in 2021
04/16ASTRAZENECA  : Covid-19 - Lagos, Kano Lead As Nigeria Vaccinates Over 1m Persons
04/16MARKET CHATTER : Johnson & Johnson Reportedly Asked Other COVID-19 Vaccine Produ..
04/16ASTRAZENECA  : Australia's Medicine Watchdog Links Woman's Death To AstraZeneca ..
More news
Financials (USD)
Sales 2021 30 805 M - -
Net income 2021 5 064 M - -
Net Debt 2021 11 692 M - -
P/E ratio 2021 26,1x
Yield 2021 2,79%
Capitalization 134 B 134 B -
EV / Sales 2021 4,73x
EV / Sales 2022 4,09x
Nbr of Employees 76 100
Free-Float 95,8%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 129,60 $
Last Close Price 102,07 $
Spread / Highest target 62,6%
Spread / Average Target 27,0%
Spread / Lowest Target -7,74%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.09%422 260
ROCHE HOLDING AG0.16%289 178
PFIZER INC.2.15%209 739
NOVARTIS AG-3.73%197 072
MERCK & CO., INC.-5.29%194 049